FMED stock forecast, quote, news & analysis

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW), Humana (NYSE:HUM), Centene Corp (NYSE:CNC), Align Technology (NASDAQ:ALGN).

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

The average market capitalization across the Fidelity Disruptive Medicine ETF ETF is 51.62B. The market cap for tickers in the group ranges from 68.04M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is ALXO at 68.04M.

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was -6%. For the same ETF, the average monthly price growth was -5%, and the average quarterly price growth was 0%. NTRA experienced the highest price growth at 9%, while VERV experienced the biggest fall at -24%.

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 3%. For the same stocks of the ETF, the average monthly volume growth was 81% and the average quarterly volume growth was 78%